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Purpose: A retrospective study based on a conventional medical practice was performed to 
evaluate the outcome of alendronate treatment for four years in Japanese men with osteoporosis 
or osteopenia and clinical risk factors for fractures.
Methods: Twenty-nine Japanese men with osteoporosis or osteopenia and clinical risk factors 
for fractures (mean age at baseline 61.0 years) who had been treated with alendronate for over 
four years in our outpatient clinic were studied. Lumbar spine or total hip bone mineral density 
(BMD) was measured using dual energy x-ray absorptiometry, and urinary levels of cross-linked 
N-terminal telopeptides of type I collagen (NTX) and serum levels of bone-specific alkaline 
phosphatase were monitored during the four-year treatment period.
Results: Urinary NTX and serum bone-specific alkaline phosphatase levels decreased (−44.4% 
at three months and −61.2% at four years, respectively) and lumbar spine and total hip BMD 
increased (+13.9% and +9.2% at four years, respectively), compared with baseline values. No 
serious adverse events were observed, including osteonecrosis of the jaw, femoral diaphysis 
atypical fractures, or atrial fibrillation.
Conclusion: To our knowledge, this is the first report of the outcome of alendronate treatment 
for four years in Japanese men with an increased risk for fractures. Alendronate suppressed 
bone turnover and increased lumbar spine and total hip BMD from baseline over the course of 
the four-year treatment period without causing any severe adverse events in Japanese men with 
osteoporosis or osteopenia and clinical risk factors for fractures.
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Introduction
Osteoporosis most commonly affects postmenopausal women, placing them at 
a significant risk for fractures. Alendronate is widely used for the treatment of 
postmenopausal osteoporosis. The Fracture Intervention Trial demonstrated the 
antifracture efficacy of alendronate for vertebral, nonvertebral, hip, and wrist fractures 
in postmenopausal women with osteoporosis.1,2 A recent systematic review analyzing 
11 randomized controlled trials including 12,068 women confirmed both clinically 
important and statistically significant reductions in vertebral, nonvertebral, hip, and 
wrist fractures for secondary prevention, ie, gold level evidence.3 Alendronate is 
regarded as a first-line drug for the treatment of osteoporosis in Japan.
Because increasing longevity has increased the public health burden of osteoporotic 
fractures in men, considerable attention has been paid to osteoporosis in this group. 
Alendronate has been approved by the US Food and Drug Administration for the 
treatment of osteoporosis in men. However, the efficacy of alendronate for osteoporosis Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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in men is not as firmly established as it is in women, because 
only a few strictly conducted randomized controlled trials 
have been performed examining the efficacy of alendronate 
in men with osteoporosis.4,5
Several studies have reported the effects (over 1–3 years) 
of alendronate or risedronate on bone mineral density (BMD) 
and bone turnover in men with osteoporosis.4–9 However, to our 
knowledge, no data showing the long-term (more than three 
years) effects of alendronate on BMD and bone turnover in 
Japanese men with osteoporosis have been reported. Thus, a 
retrospective study based on a conventional medical practice 
was performed to evaluate the outcome of alendronate treatment 
for four years in Japanese men with an increased risk for 
fractures. The primary endpoint was BMD, and the secondary 
endpoints were biochemical markers. Adverse events, such as 
osteonecrosis of the jaw, femoral atypical diaphysis fractures, 
and atrial fibrillation,10–12 as well as incident osteoporotic 
fractures (at the vertebrae, hip, wrist, and proximal humerus, 
were assessed). We believe that the data presented in this paper 
may provide physicians who treat patients in Asia with useful 
information, because there are no reports showing the long-term 
effect of alendronate treatment on BMD and bone turnover in 
Asian men with an increased risk for fractures.
Methods and materials
subjects
Twenty-nine men with osteoporosis or osteopenia and 
clinical risk factors for fractures (mean age 61.0 years at 
the beginning of treatment) who had been treated with alen-
dronate (5 mg daily or 35 mg weekly) for over four years 
were recruited at the outpatient clinic of Keiyu Orthopaedic 
Hospital, Gunma, Japan, during a three-month period 
between July 1 and September 30, 2010. Patients whose 
data were missing or incomplete were excluded. The doses 
indicated in parentheses are the doses used in Japan for 
treatment of postmenopausal women with osteoporosis and 
have been recognized as being safe and effective.13,14 The 
effects of daily and weekly alendronate on BMD and bone 
turnover markers, as well as the incidence of side effects, 
were reported to be similar in postmenopausal Japanese 
women with osteoporosis.14 Daily alendronate was available 
throughout the study period, but weekly alendronate only 
became available after October 2006. The patients were 
treated with daily alendronate (5 mg daily) before October 
2006 and with weekly alendronate (35 mg weekly) after 
October 2006. The subjects did not receive either elementary 
calcium or natural vitamin D supplements.
According to the Japanese diagnostic criteria,15,16 patients 
with a BMD , 70% of the young adult mean or 70%–80% 
of the young adult mean along with a history of osteoporo-
tic fractures should be diagnosed as having osteoporosis. 
Patients with a BMD of 70%–80% of the young adult mean 
without any history of osteoporotic fractures are diagnosed as 
having osteopenia. Patients with osteoporosis or osteopenia 
and clinical risk factors for fractures, such as current smok-
ing, alcohol abuse ($2 U/day), a history of steroid use, or 
a maternal family history of hip fracture, are treated with 
drugs.17 One alcohol unit is measured as 20 g pure alcohol. 
This equals a unit (180 mL) of Japanese wine (alcohol by 
volume [ABV] 15%), a bottle (500 mL) of Japanese beer 
(ABV 5%), a quarter (180 mL) of a bottle of red wine (ABV 
14%), one 60 mL double measure of whisky (ABV 43%), 
or 0.6 unit (110 mL) of shochu (a clear liquor, ABV 25%). 
Lumbar spine or total hip BMD was used for diagnosis of 
osteoporosis. BMD was able to be evaluated only at one 
skeletal site among the lumbar spine, hip, distal radius, and 
calcaneus because of medical insurance regulations in Japan. 
Dual-energy x-ray absorptiometry at our facility was used 
to measure BMD of the lumbar spine and total hip, both of 
which are clinically important skeletal sites in the treatment 
of osteoporosis. BMD was measured at the lumbar spine 
before December 2004 because the spine was considered to 
be an important skeletal site in the treatment of osteoporosis, 
based on a report that showed a higher incidence of vertebral 
fractures in Japanese than in Caucasians.18 However, BMD 
was measured at the total hip after January 2005 because 
hip BMD had been paid attention to as a result of a report 
suggesting use of the proximal femur with dual-energy x-ray 
absorptiometry (as the recommended site) for diagnosis in 
the assessment of fracture risk.19 All patients in the present 
study had been diagnosed as having osteoporosis or osteope-
nia and had at least one of the aforementioned clinical risk 
factors for fractures.
Preliminary screening included a medical history, 
physical examination, plain x-rays of the thoracic and lumbar 
spine, lumbar spine (n = 15) or total hip (n = 14) BMD mea-
surement, and blood and urinary biochemical tests includ-
ing serum calcium, phosphorus, and bone-specific alkaline 
phosphatase as a bone formation marker and urinary cross-
linked N-terminal telopeptides of type I collagen (NTX) as 
a bone resorption marker. Subjects with a history of reflux 
esophagitis or gastric or duodenal ulcers were excluded. None 
of the subjects had ever taken medication for treatment of 
osteoporosis prior to the present study.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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The measurement of urinary NTX levels is permitted 
only twice (just before and within six months after the start 
of medication) in Japan because of medical insurance regula-
tions. Thus, we evaluated urinary NTX at three months after 
the start of treatment, because a urinary NTX measurement 
performed at this stage provides important information 
and is sufficient to monitor the effects of treatment for 
  osteoporosis.20 Serum levels of calcium, phosphorus, and 
bone-specific alkaline phosphatase, and lumbar spine or total 
hip BMD, were measured every six months after the start 
of treatment. After four years of treatment, plain x-rays of 
the thoracic and lumbar spine were taken to assess incident 
vertebral fractures. Incident clinical fractures were also 
assessed. The outcome of alendronate treatment for four years 
was then evaluated. The present study was approved by the 
Ethics Committee of Keiyu Orthopaedic Hospital.
Vertebral fractures
Plain lateral x-ray films of the thoracic and lumbar spine 
were obtained at baseline to detect evidence of morphomet-
ric vertebral fractures. According to the Japanese criteria, a 
vertebral fracture was defined according to vertebral height 
on lateral x-ray films.15,16 Briefly, vertebral height was mea-
sured at the anterior (A), central (C), and posterior (P) parts 
of the vertebral body, and the presence of a vertebral fracture 
was confirmed when: a reduction in the vertebral height of 
more than 20% (A, C, and P) compared with the height of 
the adjacent vertebrae was observed; the C/A or C/P was 
less than 0.8; or the A/P was less than 0.75. Assessment for 
vertebral fractures was performed at the T4–L4 level.
Lumbar spine or total hip BMD
BMD at the lumbar spine (L1–L4) or the left total hip in 
the AP view was measured using dual-energy x-ray absorp-
tiometry (with Hologic QDR 1500 W apparatus, Bedford, 
MA). The coefficient of variation (100 × standard deviation 
[SD]/mean) of five measurements with repositioning within 
72 hours each time was less than 1.2% for three persons.
Serum calcium, phosphorus, bone-specific 
alkaline phosphatase, and urinary nTX 
Serum calcium and phosphorus levels were measured using 
standard laboratory techniques (normal range 8.4–10.2 mg/dL, 
2.5–4.5 mg/dL, and 135–310 IU/L, respectively). Serum 
bone-specific alkaline phosphatase levels were measured 
using an enzyme immunoassay.   Urinary NTX levels were 
measured using an enzyme-linked immunosorbent assay. 
Normal ranges of urinary NTX and serum bone-specific 
alkaline phosphatase in men were not established in Japan.
statistical analysis
Data were expressed as the mean ± SD. The unpaired t-test 
or Fisher’s Exact test was used to compare data between the 
two groups. Analysis of variance (ANOVA) with Fisher’s 
protected least significant difference (PLSD) test was used 
to compare data among the time points (post hoc analysis). 
One-way ANOVA with repeated measurements was used to 
determine the significance of longitudinal changes in BMD 
and biochemical markers. Two-way ANOVA with repeated 
measurements was used to compare longitudinal changes in 
BMD and biochemical markers between the lumbar spine 
and total hip groups. All statistical analyses were performed 
using the Stat View-J 5.0 program on a Windows com-
puter. A significance level of P , 0.05 was used for all the 
comparisons.
Results
Baseline characteristics of study subjects
Table 1 shows the characteristics of the study subjects at the 
start of alendronate treatment. The mean age was 61.0 years. 
Table 1 Characteristics of study subjects at the start of treatment
Mean ± SD Range
number of subjects 29
Age (years) 61.0 ± 13.1 34–80
height (m) 1.63 ± 0.08 1.50–1.79
Body weight (kg) 57.1 ± 10.1 38–75
Body mass index (kg/m2) 21.4 ± 3.0 16.8–6.9
Current smoking [n (%)] 13 (44.8)
Alcohol abuse [2 units/day, n (%)] 6 (20.7)
history of steroid use [n (%)] 4 (13.8)
Maternal family history 1 (3.4)
of hip fracture [n (%)]
Lumbar spine BMD (g/cm2) 0.679 ± 0.110 0.446–0.804
%YAM of lumbar spine BMD (%) 65.7 ± 10.8 43–78
Total hip BMD (g/cm2) 0.674 ± 0.098 0.486–0.768
%YAM of total hip BMD (%) 68.3 ± 7.8 51–72
Urinary nTX (nM BCe/mM Cr) 61.3 ± 26.1 32.2–144.5
serum calcium (mg/dL) 9.4 ± 0.5 8.7–10.3
serum phosphorus (ng/dL) 3.1 ± 0.7 2.2–5.6
serum BsAP (U/L) 31.0 ± 10.2 13.6–50.9
number (%) of patients 13 (44.8)
with vertebral fracture
number of vertebral fracture/patient 1.28 ± 2.10 0–9
Note: The BMD was measured at the lumbar spine for 15 patients and at the hip 
for 14 patients. 
Abbreviations: sD, standard deviation; BMD, bone mineral density; YAM, young 
adult mean; nTX, cross-linked n-terminal telopeptides of type I collagen; BCe, bone 
collagen equivalent; BSAP, bone-specific alkaline phosphatase.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Thirteen subjects (44.8%) were current smokers, six (20.7%) 
were alcohol abusers ($2 U/day), four (29%) had a history 
of steroid use, and one (3.4%) had a maternal family history 
of hip fracture. Mean lumbar spine and total hip BMD were 
0.679 g/cm2 (65.7% of the young adult mean) and 0.674 g/cm2 
(68.3% of the young adult mean), respectively. Twenty 
subjects (69.0%) were diagnosed as having osteoporosis, 
and nine (31.0%) were diagnosed as having osteopenia in 
addition to clinical risk factors for fractures. Mean urinary 
NTX level was 61.3 nM BCE/mM Cr, and mean serum 
level of bone-specific alkaline phosphatase was 31.0 U/L. 
Thirteen subjects (44.8%) had prevalent vertebral fractures, 
and the mean number of prevalent vertebral fractures per 
subject was 1.28.
The past histories of subjects that could affect bone 
metabolism were steroid use (hearing loss [n = 1], nephritis 
[n = 1], subacute thyroiditis [n = 1], and Vogt-Koyanagi-
Harada disease [n = 1]), diabetes mellitus (n = 1), hepatitis 
(n = 1), gastrectomy (n = 1), and cerebrovascular disease 
with no apparent hemiplegia (n = 1). Urinary NTX levels and 
serum bone-specific alkaline phosphatase levels at baseline 
were similar in those with and those without such illnesses 
(according to the unpaired t-test).
Table 2 shows the characteristics of the study subjects 
at the start of alendronate treatment divided by the BMD 
measurement site. Body weight and body mass index were 
significantly greater in the total hip group than in the lumbar 
spine group (according to the unpaired t-test). However, 
there were no significant differences in other characteristics 
between the two groups (according to the unpaired t-test or 
Fisher’s Exact test).
Lumbar or total hip BMD  
and biochemical markers
Figure 1 shows a continuous increase in lumbar spine and 
total hip BMD over the four-year study period. Table 3 and 
Figure 2 show that the rates of increase for lumbar BMD 
after years 1, 2, 3, and 4 of treatment compared with baseline 
values were 8.0%, +10.0%, +11.4%, and +13.9%, respectively, 
while the rates of increase for the total hip BMD compared 
with baseline values were +3.8%, +4.7%, 6.8%, and +9.2%, 
respectively. The post hoc analysis (ANOVA with Fisher’s 
PLSD test) showed significant increases in lumbar spine BMD 
at 42 and 48 months compared with baseline values, but did 
not show any significant increases in total hip BMD at any 
time points compared with baseline values. However, one-way 
ANOVA with repeated measurements detected significant 
increases in both lumbar spine and total hip BMD (Table 3).
Figure 3 shows the changes in biochemical markers. 
Urinary NTX levels decreased after three months of treatment 
and serum bone-specific alkaline phosphatase levels decreased 
after six months of treatment and continued to decrease there-
after. Table 3 shows that the mean change in urinary NTX 
levels after three months of treatment compared with baseline 
values was −44.4%. Mean change in serum bone-specific alka-
line phosphatase levels after one year of treatment compared 
with baseline values was −42.5%, and this effect continued 
to decrease gradually over the course of the four-year treat-
ment period (−48.0% at two years, −55.5% at three years, and 
−61.2% at four years). The post hoc analysis (ANOVA with 
Fisher’s PLSD test) showed a significant decrease in urinary 
NTX levels at three months compared with baseline values, 
and significant decreases in serum bone-specific alkaline 
phosphatase levels at all time points compared with baseline 
values. One-way ANOVA with repeated measurements 
detected significant decreases in both urinary NTX and serum 
bone-specific alkaline phosphatase levels (Table 3).
The post hoc analysis showed a significant decrease in 
serum calcium levels at 30, 42, and 48 months compared with 
baseline values, but did not show any significant decreases 
in serum phosphorus levels at any time points compared 
with baseline values. One-way ANOVA with repeated 
Table 2 Characteristics of study subjects at the start of treatment 
divided by BMD measurement site
Lumbar  
spine
Total hip P values
number of subjects 15 14
Age (years) 59.6 ± 11.6 62.7 ± 14.6 ns
height (m) 1.64 ± 0.08 1.62 ± 0.08 ns
Body weight (kg) 61.5 ± 8.7 53.1 ± 10.1 ,0.05
Body mass index (kg/m2)  22.6 ± 3.3 20.1 ± 2.1 ,0.05
Current smoking [n (%)] 6 (40.0) 7 (50.0) ns
Alcohol abuse  
[2 units/day, n (%)]
3 (20.0) 3 (21.4) ns
history of steroid use [n (%)] 2 (13.3) 2 (14.3) ns
Maternal family history 1 (6.7) 0 (0.0) ns
of hip fracture [n (%)]
Urinary nTX  
(nM BCe/mM Cr)
53.1 ± 13.8 68.9 ± 33.0 ns
serum calcium (mg/dL) 9.4 ± 0.5 9.5 ± 0.4 ns
serum phosphorus (ng/dL) 2.8 ± 0.4 3.2 ± 0.5 ns
serum BsAP (U/L) 28.8 ± 9.7 31.7 ± 11.0 ns
number (%) of patients 3 (20.0) 10 (71.4) ns
with vertebral fracture
number of vertebral  
fracture/patient
1.86 ± 2.45 0.73 ± 1.62 ns
Notes: Data are expressed as means ± standard deviation. The unpaired t-test or 
Fisher’s exact test was used to compare data between the two groups. 
Abbreviations:  BMD,  bone  mineral  density;  nTX,  cross-linked  n-terminal 
telopeptides of type I collagen; BCE, bone collagen equivalent; BSAP, bone-specific 
alkaline phosphatase; NS, not significant.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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measurements did not detect any significant changes in either 
serum calcium and phosphorus levels (Table 3).
Longitudinal changes in BMD and biochemical markers, 
such as urinary NTX, serum bone-specific alkaline phos-
phatase, calcium, and phosphorus did not differ significantly 
between the lumbar spine and total hip groups (by two-way 
ANOVA with repeated measurements).
Incident fractures
During the four-year treatment period, two patients experi-
enced vertebral fractures. One patient experienced fractures 
at T10 and T11 and another at L1. The BMD of the former 
patient was evaluated at the lumbar spine, and that of the latter 
patient at the hip. However, none of the patients experienced 
hip, wrist, or proximal humerus fractures. The incidence of 
vertebral fractures was 6.9%.
Adverse events
No serious adverse events, including osteonecrosis of the 
jaw, femoral atypical diaphysis fractures, or atrial fibrilla-
tion, were observed.
Discussion
The present study confirmed that alendronate suppressed 
bone turnover and increased lumbar spine or total hip BMD, 
compared with baseline values, over a four-year treatment 
period without causing any severe adverse events, including 
osteonecrosis of the jaw, femoral atypical diaphysis fractures, 
or atrial fibrillation.
The higher risk of osteoporotic fractures in men is consid-
ered to accrue from a lower peak volumetric BMD and greater 
bone loss with aging, particularly among those subjects with 
risk factors, hypogonadism, or underlying illness.21 Bone 
formation, as reflected by bone formation markers, likely 
decreases with aging and in the presence of fractures in men.21 
On the other hand, bone resorption, as reflected by bone 
resorption markers, may increase late in life, probably reflect-
ing an increase in bone turnover associated with secondary 
hyperparathyroidism.21 However, whether osteoporosis in 
men is caused mainly by increased bone resorption remains 
controversial, even though increased or decreased bone turn-
over has been reported in men with vertebral fractures.22,23 
In the present study, eight patients (27.6%) had some illness 
that could affect bone metabolism. However, urinary NTX 
levels and serum bone-specific alkaline phosphatase levels 
at baseline were similar in both those with and those without 
such illnesses. In total, 44.8% of the subjects had prevalent 
vertebral fractures (mean number 1.28). The efficacy of 
antiresorptive drugs, such as alendronate, can be expected 
in our subjects with an increased risk for fractures.
Studies have shown that alendronate decreases urinary 
NTX (−42% at three months) and serum bone-specific 
alkaline phosphatase (about −33% at six months) levels and 
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Figure 1 Changes in bone mineral density. The BMD was measured at the lumbar spine for 15 patients and at the hip for 14 patients. Data were expressed as the 
mean ± standard deviation. Post hoc analysis showed significant increases in lumbar spine BMD at 42 and 48 months compared with baseline values, but did not show any 
significant increases in total hip BMD at any time points compared with baseline values. However, one-way ANOVA with repeated measurements detected significant 
increases in both lumbar spine and total hip BMD. 
Note: *P , 0.05 versus baseline values by AnOVA with Fisher’s PLsD test.
Abbreviations: BMD, bone mineral density; ANOVA, analysis of variance; PLSD, protected least significant difference.
Table 3 Percent changes in BMD and bone turnover markers 
compared with baseline values
3 mos 1 yr 2 yrs 3 yrs 4 yrs P values
Lumbar spine BMD +8.0 +10.0 +11.4 +13.9 ,0.0001
Total hip BMD +3.8 +4.7 +6.8 +9.2 ,0.001
Urinary nTX −44.4 ,0.0001
serum BsAP −42.5 −48.0 −55.5 −61.2 ,0.0001
Note: One-way AnOVA with repeated measurements was used to determine the 
significance of changes in BMD and bone turnover markers. 
Abbreviations:  BMD,  bone  mineral  density;  nTX,  cross-linked  n-terminal 
telopeptides of type I collagen; AnOVA, analysis of variance.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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increases the lumbar spine, femoral neck, and total hip BMD 
(+8.8%–11.5%, 4.2%–5.8%, and 3.9%, respectively, at three 
years) in men with osteoporosis.5–7 In the present study, uri-
nary NTX and serum BAP levels decreased (−44.4% at three 
months and −61.2% at four years, respectively) and lumbar 
spine and total hip BMD increased (+13.9% and +9.2% at 
four years, respectively), compared with baseline values. 
Reduction in serum bone-specific alkaline phosphatase 
and increase in BMD were greater in our subjects than in 
Western men with osteoporosis, probably because of higher 
bone turnover at baseline according to the normal ranges of 
urinary NTX and serum bone-specific alkaline phosphatase 
in healthy premenopausal women (9.3–54.3 nM BCE/mM Cr 
and 7.9–29.0 U/L, respectively).24 Normal ranges for these 
bone turnover parameters in men were not established in 
Japan. Our previous study showed that urinary NTX levels 
were not higher in men with osteoporosis than in postmeno-
pausal women with osteoporosis.25
Serum bone-specific alkaline phosphatase levels 
decreased after six months of treatment and continued to 
decrease thereafter. The mean change in serum bone-specific 
alkaline phosphatase levels after four year of treatment com-
pared with baseline values was −61.2%. Postmenopausal 
women treated with alendronate with the greatest percent 
reduction in bone-specific alkaline phosphatase have the 
lowest risk of hip fractures, while those with the smallest 
reduction in bone-specific alkaline phosphatase have the 
highest risk.26 Alendronate-treated postmenopausal women 
with a reduction in bone-specific alkaline phosphatase of at 
least 30% have a 74% lower risk of hip fractures, compared 
with those having a less than 30% reduction.26 Although the 
efficacy of alendronate against vertebral fractures seems to 
have been established in men with osteoporosis,27 the effi-
cacy of alendronate with regard to reduction in risk of hip 
fractures remains to be established, probably because of the 
insufficient sample sizes for randomized controlled trials. 
Thus, the improvement of surrogate markers, such as hip 
BMD and bone turnover markers, is thought to be important 
for preventing hip fractures in men with an increased risk 
of fractures.
A cohort study in Japan revealed that the incidence (per 
1000 person-years) of vertebral fractures in male atomic 
bomb survivors aged 60–69 years in Hiroshima and Nagasaki 
was 6.5 in the absence of prevalent vertebral fractures and 
31.5 in the presence of prevalent vertebral fractures. Namely, 
the respective incidence of vertebral fractures during a four-
year period was considered to be 2.6% and 12.6% (average 
7.6%).18 The incidence of vertebral fractures at four years 
was 6.9% in our study subjects (mean age 61.0 years, and 
44.8% of subjects had prevalent vertebral fractures), suggest-
ing a relatively high incidence of vertebral fractures despite 
receiving alendronate therapy. One possible explanation for 
this result might be the higher proportion of patients with 
prevalent vertebral fractures in terms of the higher risk of 
incident fractures at baseline. Another possibility might be 
the existence of subclinical osteomalacia on a background 
of significantly decreased serum calcium levels because of 
lack of calcium and vitamin D supplementation.
The strength of the present study is that it is the first report 
of the outcome of alendronate treatment for four years in 
Japanese men with an increased risk for fractures. However, 
the present study has some notable limitations. First, it was 
a retrospective study with a small sample size based on a 
conventional medical practice. Second, we confirmed that 
there were no severe adverse events, including osteonecrosis 
of the jaw, femoral atypical diaphysis fractures, and atrial 
fibrillation in patients who were treated with alendronate 
over four years. However, because we were not able to 
recruit patients who dropped out from alendronate treat-
ment, the true incidence of adverse events with alendronate 
treatment remains uncertain. Third, the subjects did not 
receive either elementary calcium or natural vitamin D 
supplementation, which is not prevalent in Japan. This 
circumstance makes it difficult to compare the present study 
with others, because most other studies have involved men 
with osteoporosis who have taken calcium and vitamin D 
supplements. Prospective studies with a large number of 
subjects are needed to establish the long-term efficacy and 
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Figure 2 Mean percent changes in bone mineral density from baseline. The BMD 
was measured at the lumbar spine for 15 patients and at the hip for 14 patients. 
Rates of increase for the lumbar BMD after treatment years 1, 2, 3, and 4 compared 
with  baseline  values  were  +8.0%,  +10.0%,  +11.4%,  and  +13.9%,  respectively, 
while the rates of increase for the total hip BMD compared with baseline values 
were +3.8%, +4.7%, +6.8% and +9.2%, respectively. 
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safety of alendronate treatment in combination with calcium 
and vitamin D supplementation in Japanese men with an 
increased risk for fractures.
In conclusion, the present study confirmed that alen-
dronate suppressed bone turnover and increased lumbar spine 
and total hip BMD from baseline over the course of a four-
year treatment period without causing any severe adverse 
events in Japanese men with osteoporosis or osteopenia and 
clinical risk factors for fractures.
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Figure 3 Changes in biochemical markers. Data were expressed as the mean ± standard deviation. Post hoc analysis showed a significant decrease in urinary NTX levels at 
three months compared with baseline values, and significant decreases in serum bone-specific alkaline phosphatase levels at all time points compared with baseline values. 
One-way ANOVA with repeated measurements detected significant decreases in both urinary NTX and serum bone-specific alkaline phosphatase levels. Post hoc analysis 
showed a significant decrease in serum calcium levels at 30, 42, and 48 months compared with baseline values, but did not show any significant decreases in serum phosphorus 
levels at any time points compared with baseline values. One-way ANOVA with repeated measurements did not detect any significant changes in both serum calcium and 
phosphorus levels.
Notes: *P , 0.05; #P , 0.001 versus baseline values by AnOVA with Fisher’s PLsD test.
Abbreviations: nTX, cross-linked N-terminal telopeptides of type I collagen; BSAP, bone-specific alkaline phosphatase; ANOVA, analysis of variance; PLSD, protected 
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